Andriandi et al (2019) Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution. Ann Med Surg (Lond) 41:11-15. https://doi: 10.1016/j.amsu.2019.03.011
Avivi I et al (2019) Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol 94(10):1132-1140. https://doi: 10.1002/ajh.255
Batsukh K et al (2017) Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma. Immune Netw 17(4):250-260. https://doi: 10.4110/in.2017.17.4.250
Besse L et al (2016) Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol 97(1):93-100. https:// doi: 10.1111/ejh.12688.
Bhutani M et al (2020) Extramedullary multiple myeloma. Leukemia 34(1):1-20. https://doi: 10.1038/s41375-019-0660-0
Boyd KD et al (2011) Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev 20(8):1703-7. https://doi: 10.1158/1055-9965
Cavo M et al (2020) Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol 7(6):e456-e468. https://doi: 10.1016/S2352-3026(20)30099-5
Czyż J et al (2020) Autologous stem cell transplantation in the treatment of multiple myeloma with 17p deletion. Pol Arch Intern Med 130(2):106-111. https://doi: 10.20452/pamw.15139
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica 103(5):890-897. https://doi: 10.3324/haematol
Gagelmann N et al (2019) Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 25(11):2134-2142. https://doi: 10.1016/j.bbmt.2019.07.004
Guillermo CL et al (2007) Clinical features and survival of Chilean patients with multiple myeloma. Rev Med Chil 135(9):1111-7. https://doi: 10.4067/s0034-98872007000900003
He JS et al (2021) Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma. Front Oncol 11:668099. https://doi: 10.3389/fonc.2021.668099
Ikeda T et al (2019) Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiplemyeloma relapsing/progressing after autologous stem cell transplantation. Hematol Oncol 37(5):586-594. https://doi: 10.1002/hon.2688
Jagosky MH, Usmani SZ (2020) Extramedullary Disease in Multiple Myeloma. Curr Hematol Malig Rep 15(2):62-71. https://doi: 10.1007/s11899-020-00568-3.
Jayakrishnan TT et al (2021) Disparities in the enrollment to systemic therapy and survival for patients with multiple myeloma. Hematol Oncol Stem Cell Ther 14(3):218-230. https://doi: 10.1016/j.hemonc.2020.09.005
Kumar S et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8): e328-e346. https://doi:10.1016/S1470-2045(16)30206-6
Kumar SK et al (2020). Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21(10):1317-1330. https://doi: 10.1016/S1470-2045(20)30452-6
Kumar SK et al (2017) Multiple myeloma. Nat Rev Dis Primers 3:17046. https://doi: 10.1038/nrdp.2017.46
Laura R et al (2006) Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 76(5): 405-408. https://doi: 10.1111/j.0902-4441.2005.t01-1-EJH2
462.x
Liu Y et al (2020) Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma. Am J Surg Pathol 44(6):838-848. https://doi: 10.1097/PAS.0000000000001459
Montefusco V et al (2019) Outcome of Paraosseous Extra-Medullary Disease in Newly Diagnosed Multiple Myeloma Patients Treated With New Drugs. Haematologica 105(1):193–200. https://doi: 10.3324/haematol.2019.219139
O'Donnell EK et al (2018) A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol 182(2):222-230. https://doi: 10.1111/bjh.15261
Rajkumar SV et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538-48. https://doi: 10.1016/S1470-20
45(14)70442-5
Rosiñol L et al (2004). Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 89(7):832-836.
Tian C et al (2018). Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis. Biosci Rep 38(3):BSR20171697. https://doi: 10.1042/BSR20171697
Touzeau C, Moreau P (2016) How I treat extramedullary myeloma. Blood 127:971–6.
Varettoni M et al ( 2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21(2):325–30. https://doi: 10.1093/annonc/mdp329.
Wang J et al (2020). Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease. Zhonghua Xue Ye Xue Za Zhi 41(10):822-828. https://doi: 10.3760/cma.j.issn.0253-2727.2020.10.006
Zhang Y et al (2019) Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. Biomed Res Int 5652935. https://doi: 10.1155/2019/5652935